(CercleFinance.com) – GSK unveiled new clinical data on Tuesday showing that its shingles vaccine Shingrix retained its effectiveness for more than ten years in patients aged over 50.
According to the follow-up results of a phase III study, the effectiveness of its product reached 79.7% within this population between the six and 11 years following vaccination.
This rate even rises to 82% among people aged over 50 after 11 years of vaccination.
Among those over 70, its effectiveness stood at 73.1% between six and 11 years following vaccination.
It is estimated that 30% of the population will one day develop shingles, a disease caused by the chickenpox virus, a proportion that rises to almost 50% among people who live to age 85.
Copyright © 2024 CercleFinance.com. All rights reserved.
Did you like this article ? Share it with your friends using the buttons below.
